HOOKIPA Pharma (NASDAQ:HOOK) underwent analysis by 4 analysts in the last quarter, revealing a spectrum of viewpoints from bullish to bearish.
The table below provides a concise overview of recent ratings by analysts, offering insights into the changing sentiments over the past 30 days and drawing comparisons with the preceding months for a holistic perspective.
Bullish
Somewhat Bullish
Indifferent
Somewhat Bearish
Bearish
Total Ratings
2
2
0
0
0
Last 30D
0
1
0
0
0
1M Ago
1
0
0
0
0
2M Ago
1
1
0
0
0
3M Ago
0
0
0
0
0
Providing deeper insights, analysts have established 12-month price targets, indicating an average target of $5.38, along with a high estimate of $6.50 and a low estimate of $5.00. A decline of 17.23% from the prior average price target is evident in the current average.
Decoding Analyst Ratings: A Detailed Look
In examining recent analyst actions, we gain insights into how financial experts perceive HOOKIPA Pharma. The following summary outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
Analyst
Analyst Firm
Action Taken
Rating
Current Price Target
Prior Price Target
Brian Abrahams
RBC Capital
Maintains
Outperform
$5.00
-
Arthur He
HC Wainwright & Co.
Lowers
Buy
$5.00
$6.50
Brian Abrahams
RBC Capital
Maintains
Outperform
$5.00
-
Arthur He
HC Wainwright & Co.
Maintains
Buy
$6.50
-
Key Insights:
Action Taken: Analysts respond to changes in market conditions and company performance, frequently updating their recommendations. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their ...Full story available on Benzinga.com
Benzinga
